Companies Dominating the Lymphoproliferative Disorder Treatment Landscape
- Atara Biotherapeutics, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Merck & Co., Inc.
- Bristol Myers Squibb Company
- Genentech, Inc.
- ADC Therapeutics SA
- AbbVie Inc.
- Novartis AG
- Pfizer Inc.
- AstraZeneca
- Gilead Sciences, Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of lymphoproliferative disorder treatment is evaluated at USD 6.32 billion.
The lymphoproliferative disorder treatment market size was over USD 5.69 billion in 2024 and is projected to reach USD 13.22 billion by 2037, witnessing around 6.7% CAGR during the forecast period i.e., between 2025-2037. Worldwide expanding prevalence of lymphoma cases, rise in the cases of chronic lymphocytic leukemia (CLL), and an upsurge in novel targeted treatments will boost the market growth.
North America industry is anticipated to hold largest revenue share of 45% by 2037, propelled by increasing frequency of the lymphoproliferative disorder in the region along with an increase in focus on research and development for the effective treatment of such disorders.
The major players in the market are Atara Biotherapeutics, Inc., Merck & Co., Inc., Bristol Myers Squibb Company, Genentech, Inc., ADC Therapeutics SA, AbbVie Inc., Novartis AG, Pfizer Inc., AstraZeneca, Gilead Sciences, Inc.
